Clinical application of C-reactive protein, leukocyte and immunoglobulin in the diagnosis and treatment of infantile pneumonia at acute stage

This study aims to explore the clinical significance of C-reactive protein, leukocyte and immunoglobulin in the diagnosis and treatment of infantile pneumonia at acute stage. From January to December 2018, a total of 124 children with pneumonia and healthy children admitted to our hospital were selected as study objects. Among them, 62 children diagnosed with bacterial pneumonia were categorized as the study group, and 62 healthy children who came for physical examination were classified as the control group. The levels of C-reactive protein (CRP), white blood cell (WBC) and immunoglobulin (IgA, IgM and IgG) were observed and compared in the two groups. In this study, higher levels of CRP, IgM, IgG and WBC, along with lower level of IgA were observed in the study group as compared with that in the control group. In the study group, the levels of CRP, IgM, IgG and WBC were lower, but the IgA level was higher in children with mild pneumonia than those with severe pneumonia. After treatment, the levels of CRP, IgM, IgG and WBC were decreased but IgA level was increased after treatment compared with before treatment. In particular, the levels of CRP, WBC, IgA, IgM and IgG in the study group after treatment were restored to comparable levels compared with the control group. Therefore, C-reactive protein, leukocyte and immunoglobulin can be used to determine the diagnosis, condition and outcome of children with pneumonia in the acute stage. This study can provide guidance for clinical diagnosis and treatment of infantile pneumonia based on the alterations of these indicators.

C-reactive protein; White blood cells; Immunoglobulin; Acute stage; Infantile pneumonia

[1] Marzollo A, Conti F, Rossini L, Rivalta B, Leonardi L, Tretti C, et al. Neonatal manifestations of chronic granulomatous disease: MAS/HLH and necrotizing pneumonia as unusual phenotypes and review of the literature. Journal of Clinical Immunology. 2022; 42: 299–311.

[2] Nenna R, Iovine E, Laudisa M, Bloise S, La Regina DP, Midulla F. Comment on Jaworska, J. et al. Consensus on the application of lung ultrasound in pneumonia and bronchiolitis in children. Diagnostics 2020, 10, 935. Diagnostics. 2021; 11: 55.

[3] Lee J, Lin J, Chen H, Wang C, Lu C, Chang L, et al. Impact of pneumococcal conjugate vaccination on hospitalized childhood pneumonia in Taiwan. Pediatric Research. 2022; 92: 1161–1167.

[4] Luo Z, Wei H, Li X. Granulocyte-macrophage colony-stimulating factor suppresses induction of type I interferon in infants with severe pneumonia. To be published in Pediatric Research. 2022. [Preprint].

[5] Roncin C, Vanel N, Morand A, Belghiti Alaoui M, Michel F. Systematic endotracheal aspiration in the pediatric intensive care unit reduces broad-spectrum antibiotic use for ventilator-associated pneumonia. Pediatric Infectious Disease Journal. 2022; 41: 544–548.

[6] Ding N, Liu D, Duan X, Zhang J, Ma S, Chen Y. Twist2 reduced NLRP3-induced inflammation of infantile pneumonia via regulation of mitochondrial permeability transition by FOXO1. International Archives of Allergy and Immunology. 2022; 183: 1098–1113.

[7] Dudognon D, Levy C, Chalumeau M, Biscardi S, Dommergues MA, Dubos F, et al. Diagnostic accuracy of routinely available biomarkers to predict bacteremia in children with community-acquired pneumonia: a secondary analysis of the GPIP/ACTIV pneumonia study in France, 2009–2018. Frontiers in Pediatrics. 2021; 9: 684628.

[8] Maggio M, Cimaz R, Failla M, Dones P, Corsello G. Typical Kawasaki disease with atypical pneumonia: a paediatric case report. Scandinavian Journal of Rheumatology. 2021; 50: 248–249.

[9] Chen L, Chen Y, Huang J, Zhang J. LncRNA LINC00707 serves as a sponge of miR-382-5p to alleviate lipopolysaccharide (LPS)-induced WI-38 cell injury through upregulating NKAP in infantile pneumonia. Autoimmunity. 2022; 55: 328–338.

[10] Yu Y, Yang T, Ding Z, Cao Y. Circ_0026579 alleviates LPS-induced WI-38 cells inflammation injury in infantile pneumonia. Innate Immunity. 2022; 28: 37–48.

[11] Cui J, Wang J, Lv Y, Xu D. LncRNA NEAT1 regulates infantile pneumonia by sponging miR-146b. Molecular Biotechnology. 2021; 63: 694–701.

[12] Zhang J, Wang CH, Liu XJ, Cheng SF, Han LH, Lv CL. Efficacy and safety analysis of dopamine combined with creatine phosphate sodium in the treatment of infantile pneumonia combined with heart failure. Journal of Biological Regulators and Homeostatic Agents. 2020; 34: 2103–2108.

[13] Iovine E, Petrarca L, Regina DP, Matera L, Mancino E, Di Mattia G, et al. The key role of lung ultrasound in the diagnosis of a mature cystic teratoma in a child with suspected difficult to treat pneumonia: a case report. Children. 2022; 9: 555.

[14] Xie F, Chen R, Zhao J, Xu C, Zan C, Yue B, et al. Cell cycle kinase CHEK2 in macrophages alleviates the inflammatory response to staphylococcus aureus-induced pneumonia. To be published in Experimental Lung Research. 2022. [Preprint].

[15] Ding N, Meng Y, Liu L, Ma S, Chen Y. Sphingosine Kinase-1 (SPHK1) promotes inflammation in infantile pneumonia by regulating NLRP3 inflammasome and SIRT1 expression. To be published in Histology and Histopathology. 2022. [Preprint].

[16] Albrijawy R, Alomar K, Aldeen RS, Sharief FAL, Saleh IEA, Hamdan O. Case report: a rare case of congenital non-metastatic low-grade fibrosarcoma of the pleura in a 6-month-old infant manifested as pneumonia. International Journal of Surgery Case Reports. 2022; 99: 107714.

[17] AlShamrani AS, Alzaid MA, Fadl SM, AlFaki MA. A case of infantile exogenous lipoid pneumonia with an unusual complication managed by modified whole lung lavage. Sudanese Journal of Paediatrics. 2021; 21: 82–88.

[18] Naraoka T, Sumi T, Keira Y, Nakata H, Chiba H. Epirubicin and cyclophosphamide-induced acute fibrinous and organizing pneumonia. American Journal of Respiratory and Critical Care Medicine. 2021; 204: e92–e93.

[19] Wu Z, Liu Y, Xu J, Xie J, Zhang S, Huang L, et al. A ventilator-associated pneumonia prediction model in patients with acute respiratory distress syndrome. Clinical Infectious Diseases. 2020; 71: S400–S408.

[20] Cornely OA, File TM, Garrity-Ryan L, Chitra S, Noble R, McGovern PC. Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairment. International Journal of Antimicrobial Agents. 2021; 57: 106263.

[21] Liang J, Yin Z, Li Z, Gu H, Yang K, Xiong Y, et al. Predictors of dysphagia screening and pneumonia among patients with acute ischaemic stroke in China: findings from the Chinese Stroke Center Alliance (CSCA). Stroke and Vascular Neurology. 2022; 7: 294–301.

[22] Ma Q, Yao C, Shi H, Xu J, Dai H, Fei Z, et al. Targeted delivery of dexamethasone in acute pneumonia. Biomaterials Science. 2021; 9: 5569–5576.

[23] Simoni C, Camozzi P, Faré PB, Bianchetti MG, Kottanattu L, Lava SAG, et al. Myositis and acute kidney injury in bacterial atypical pneumonia: systematic literature review. Journal of Infection and Public Health. 2020; 13: 2020–2024.

[24] Guo J, Cheng Y. Retraction notice to “MicroRNA-1247 inhibits lipopolysaccharides-induced acute pneumonia in a549 cells via targeting CC chemokine ligand 16” [Biomed. Pharmacother. 104 (2018) 60–68]. Biomedicine & Pharmacotherapy. 2021; 142: 111597.

[25] Lee JH, Yum H, Jamous F, Santos C, Campisi A, Surani S, et al. Diagnostic procedures and clinico-radiological findings of acute fibrinous and organizing pneumonia: a systematic review and pooled analysis. European Radiology. 2021; 31: 7283–7294.

[26] Klompas M, Branson R, Cawcutt K, Crist M, Eichenwald EC, Greene LR, et al. Strategies to prevent ventilator-associated pneumonia, ventilator-associated events, and nonventilator hospital-acquired pneumonia in acute-care hospitals: 2022 update. Infection Control & Hospital Epidemiology. 2022; 43: 687–713.

[27] Hermes Z, Joynt Maddox KE, Yeh RW, Zhao Y, Shen C, Wadhera RK. Neighborhood socioeconomic disadvantage and mortality among medicare beneficiaries hospitalized for acute myocardial infarction, heart failure, and pneumonia. Journal of General Internal Medicine. 2022; 37: 1894–1901.

[28] Leroy AG, Caillon J, Caroff N, Broquet A, Corvec S, Asehnoune K, et al. Could azithromycin be part of pseudomonas aeruginosa acute pneumonia treatment? Frontiers in Microbiology. 2021; 12: 642541.

[29] Wang Z, Cai R, Wang G, et al. Combination therapy of phage vB_KpnM_P-KP2 and gentamicin combats acute pneumonia caused by K47 serotype klebsiella pneumoniae. Frontiers in Microbiology. 2021; 12: 674068.

[30] Siegel ER, Croze RH, Fang X, Matthay MA, Gotts JE. Inhibition of the lipoxin A4 and resolvin D1 receptor impairs host response to acute lung injury caused by pneumococcal pneumonia in mice. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2021; 320: L1085–L1092.

[31] Mazzola M, Pugliese NR, Zavagli M, De Biase N, Bandini G, Barbarisi G, et al. Diagnostic and prognostic value of lung ultrasound b-lines in acute heart failure with concomitant pneumonia. Frontiers in Cardiovascular Medicine. 2021; 8: 693912.

[32] Guo Z, Hou J, Yu S, Zhang H, Yu S, Wang H, et al. Eosinophils, stroke-associated pneumonia, and outcome after mechanical thrombectomy for acute ischemic stroke. Frontiers in Aging Neuroscience. 2022; 14: 830858.

[33] Dai Y, Liu Z, Zhan H, Zhang G, Wang P, Zhang S, et al. Reduced inspiratory muscle strength increases pneumonia in patients with acute myocardial infarction. Annals of Physical and Rehabilitation Medicine. 2022; 65: 101511.